MedCity News
JANUARY 1, 2024
Biomarkers, electronic health records (EHR), genomic data, imaging data, labs, social media, wearable sensors, and more provide enormous new sources of RWD that can aid in new discoveries for the quality, efficacy, and safety of new drug therapies.
Pharmaceutical Technology
JANUARY 1, 2024
In this issue: Pharma’s efforts to curb Scope 3 emissions, understanding European Pharmaceutical legislation, and looking back at the pharma industry’s performance in 2023.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
JANUARY 1, 2024
Expanding access to the existing mental care system alone won’t solve problems if the mechanisms for providing care are inefficient and ineffective. Access must come hand-in-hand with quality of care – which is where measurement-based care (MBC) comes into play.
pharmaphorum
JANUARY 1, 2024
A lawsuit in the US is accusing Johnson & Johnson of unlawfully delaying the onset of biosimilar competition to its immunology blockbuster Stelara beyond its US patent expiry date.
MedCity News
JANUARY 1, 2024
Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.
pharmaphorum
JANUARY 1, 2024
Roche has agreed a $295 million deal to buy a point-of-care diagnostics platform from LumiraDx, which recently went into administration
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmacy Times
JANUARY 1, 2024
Because alcohol is a driver of HIV-associated comorbidities, the reduction interventions may improve the health of people with HIV.
PharmaTech
JANUARY 1, 2024
Read about the process utilized and results gained from the use of a two-phase scale-up strategy to manufacture three complex dry powder medium (DPM) formulations. The success of these projects relied on consistently producing acceptable prototype and cGMP material within the customer’s specifications and manufacturing timelines.
Pharmacy Times
JANUARY 1, 2024
According to the findings, the use of venetoclax, as well as other new therapies, improved overall survival from 28.6% to 45.3% in non-Hispanic Black patients with AML.
PharmaTech
JANUARY 1, 2024
In this project, Thermo Fisher Scientific worked with a multinational biopharmaceutical company to investigate trace element variability in its custom cell culture media. Within a year, using a risk-based, collaborative approach, both teams were able to thoroughly characterize incoming specific raw materials and implement proactive measures for reducing the risk of impurities, ultimately providing the company with a long-term risk mitigation strategy.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Copyright Clearance Center
JANUARY 1, 2024
The post Thinking Gets a Rethink appeared first on Copyright Clearance Center.
PharmaTech
JANUARY 1, 2024
The importance of successfully scaling up cell culture media cannot be overstated. Not starting the process soon enough can introduce issues with solubility, manufacturability, procurement, and cost management. This article considers technical and commercial best practices that drug developers may enact so that they, their suppliers and media manufacturers, and in turn, their cell culture media remain on the most efficient path to market.
PharmaTech
JANUARY 1, 2024
Media manufacturers must offer global redundancy at harmonized manufacturing facilities to enable streamlined capabilities–especially for their customers outsourcing proprietary cell culture media formulations. This paper details Thermo Fisher’s manufacturing equivalency approach utilized at two global facilities located in Miami, Florida, and Grand Island, New York.
Expert insights. Personalized for you.
129 
Let's personalize your content